Analysts have clear opinions on GILD.

There are 17 analysts on the Wall offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $78.33 with a high forecast of $89.00 and a low forecast of $63.00. The average price target represents a 25.07% increase from the last price of $62.63.
Gilead Sciences, Inc. (GILD) is followed by 17 analysts on the street.

Whitney Ijem from Guggenheim rates it a Hold.

Similarly, 8 days ago Cory Kasimov of J.P. Morgan Reiterated a Buy with a target of —.

The consensus on the street is Moderate Buy.

What does Gilead Sciences, Inc.(GILD) do ?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc. (GILD) Insider Trades

Multiple company employees have indulged in significant insider trading. Gilead Sciences, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

EVP,Corp Affairs, GC, Pletcher Brett A : S – Sale+OE(-$190,659) of GILD in the trading session of 2020-01-03.

EVP,Corp Affairs, GC Pletcher Brett A : S – Sale+OE(-$388,043) of GILD in the trading session of 2019-12-03.

EVP,Corp Affairs, GC Pletcher Brett A : S – Sale+OE(-$1,002,809) of Gilead Sciences, Inc. in the trading session of 2019-11-25.

Looking for stocks just like GILD?

Based on Wall Street analyst research, several stocks are similar to GILD
They are:
– PFE [Info can be found here: ]
– RHHBY [Info can be found here: ]
– GSK [Info can be found here: ]